глава "Самопроизвольный регресс злокачественных опухолей" - Рефлекторная Реабилитация Иммунитета

статья «Спорные аспекты фундаментальной онкологии» 

НИИ онкологии им. Н.Н. Петрова, Санкт-Петербург.

 

1. Abdelrazeq A.S. Spontaneous regression of colorectal cancer: a review of cases from 1900 to 2005 // Int J. Colorectal Dis.

– 2007. – Vol.22. – P.727736.

2. AlHajj M., Wicha M.S., BenitoHernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast

cancer cells // Proc Natl Acad Sci USA. – 2003. – Vol.100. – P.39833988.

3. Almog N., Ma L., Raychowdhury R., Schwager C., Erber R., Short S., Hlatky L., Vajkoczy P., Huber P.E., Folkman J., Abdollahi A.

Transcriptional switch of dormant tumors to fastgrowing angiogenic phenotype // Cancer Res. – 2009. – Vol.69. – P.836844.

4. Alsdorf W.H., Clauditz T.S., Hoenig T., Quaas A., Sirma H., Koenig A.M., Izbicki J., Sauter G., Marx A.H., Grob T.J. Intratumoral

heterogeneity of KRAS mutation is rare in nonsmallcell lung cancer // Exp. Mol. Pathol. – 2013. – Vol.94. – P.155159.

5. Aparicio S., Caldas C. The implications of clonal genome evolution for cancer medicine // N. Engl. J. Med. – 2013. –

Vol.368. – P.842851.

6. Atkins M.B., Lotze M.T., Dutcher J.P., Fisher R.I., Weiss G., Margolin K., Abrams J., Sznol M., Parkinson D., Hawkins M., Paradise

C., Kunkel L., Rosenberg S.A. Highdose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of

270 patients treated between 1985 and 1993 // J. Clin. Oncol. – 1999. – Vol.17. – P.21052116.

7. Balachandran V.P., Cavnar M.J., Zeng S., Bamboat Z.M., Ocuin L.M., Obaid H., Sorenson E.C., Popow R., Ariyan C., Rossi F.,

Besmer P., Guo T., Antonescu C.R., Taguchi T., Yuan J., Wolchok J.D., Allison J.P., DeMatteo R.P. Imatinib potentiates antitumor T cell

responses in gastrointestinal stromal tumor through the inhibition of Ido // Nat. Med. – 2011. – Vol.17. – P.10941100.

8. Blows F.M., Driver K.E., Schmidt M.K., Broeks A., van Leeuwen F.E., Wesseling J., Cheang M.C., Gelmon K., Nielsen T.O., Blomqvist

C., Heikkilд P., Heikkinen T., Nevanlinna H., Akslen L.A., Bйgin L.R., Foulkes W.D., Couch F.J., Wang X., Cafourek V., Olson J.E.,

Baglietto L., Giles G.G., Severi G., McLean C.A., Southey M.C., Rakha E., Green A.R., Ellis I.O., Sherman M.E., Lissowska J., Anderson

W.F., Cox A., Cross S.S., Reed M.W., Provenzano E., Dawson S.J., Dunning A.M., Humphreys M., Easton D.F., GarcнaClosas M., Caldas

C., Pharoah P.D., Huntsman D. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between

subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies // PLoS Med. – 2010.

– Vol.7. – e1000279.

9. Bodey B. Spontaneous regression of neoplasms: new possibilities for immunotherapy // Expert Opin Biol Ther. – 2002. – Vol.2.

– P.459476.

10. Bonanni B., Puntoni M., Cazzaniga M., Pruneri G., Serrano D., GuerrieriGonzaga A., Gennari A., Trabacca M.S., Galimberti

V., Veronesi P., Johansson H., Aristarco V., Bassi F., Luini A., Lazzeroni M., Varricchio C., Viale G., Bruzzi P., Decensi A. Dual effect of

metformin on breast cancer proliferation in a randomized presurgical trial // J. Clin. Oncol. – 2012. – Vol.30. – P.2593600.

11. Buell J.F., Trofe J., Sethuraman G., Hanaway M.J., Beebe T.M., Gross T.G., Alloway R., First M.R., Woodle E.S. Donors with

central nervous system malignancies: are they truly safe? // Transplantation. – 2003. – Vol.76. – P.340343.

12. Buell J.F., Beebe T.M., Trofe J., Gross T.G., Alloway R.R., Hanaway M.J., Woodle E.S. Donor transmitted malignancies // Ann.

Transplant. – 2004. – Vol.9. – P.5356.

13. Burrell R.A., McGranahan N., Bartek J., Swanton C. The causes and consequences of genetic heterogeneity in cancer

evolution // Nature. – 2013. – Vol.501. – P.338345.

14. Burrell R.A., Swanton C. The evolution of the unstable cancer genome // Curr Opin Genet Dev. – 2014. – Vol.24. –

P.6167.

15. Challis G.B., Stam H.J. The spontaneous regression of cancer. A review of cases from 1900 to 1987 // Acta Oncol. – 1990.

– Vol.29(5). – P.545550.

16. Clevers H. The cancer stem cell: premises, promises and challenges // Nat. Med. – 2011. – Vol.17. – P.313319.

17. Coley W.B. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases.

1893 // Clin. Orthop. Relat. Res. – 1991. – Vol.262. – P.311.

18. Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective identification of tumorigenic prostate cancer stem

cells // Cancer Res. – 2005. – Vol.65. – P.1094610951.

19. Curley M.D., Therrien V.A., Cummings C.L., Sergent P.A., Koulouris C.R., Friel A.M., Roberts D.J., Seiden M.V., Scadden D.T.,

Rueda B.R., Foster R. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer // Stem.

Cells. – 2009. – Vol.27. – P.28752883.

20. de Gramont A., Van Cutsem E., Schmoll H.J., Tabernero J., Clarke S., Moore M.J., Cunningham D., Cartwright T.H., Hecht J.R.,

Rivera F., Im S.A., Bodoky G., Salazar R., MaindraultGoebel F., ShachamShmueli E., Bajetta E., Makrutzki M., Shang A., André T.,

Hoff P.M. Bevacizumab plus oxaliplatinbased chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3

randomised controlled trial // Lancet. Oncol. – 2012. – Vol.13. – P.12251233.

21. Demicheli R., Abbattista A., Miceli R., Valagussa P., Bonadonna G. Time distribution of the recurrence risk for breast

cancer patients undergoing mastectomy: further support about the concept of tumor dormancy // Breast. Cancer. Res. Treat.

– 1996. – Vol.41. – P.177185.

22. Demicheli R., Retsky M.W., Hrushesky W.J., Baum M., Gukas I.D. The effects of surgery on tumor growth: a century of

investigations // Ann. Oncol. – 2008. – Vol.19. – P.18211828.

23. Eramo A., Lotti F., Sette G., Pilozzi E., Biffoni M., Di Virgilio A., Conticello C., Ruco L., Peschle C., De Maria R. Identification and

expansion of the tumorigenic lung cancer stem cell population // Cell Death. Differ. – 2008. – Vol.15. – P.504514.

24. Furth J., Kahn M.C. The transmission of leukaemia of mice with a single cell // Am. J. Cancer. – 1937. – Vol.31. – P.276

282.

25. Garraway L.A., Lander E.S. Lessons from the cancer genome // Cell. – 2013. – Vol.153. – P.1737.

26. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P.,

Varela I., Phillimore B., Begum S., McDonald N.Q., Butler A., Jones D., Raine K., Latimer C., Santos C.R., Nohadani M., Eklund A.C.,

SpencerDene B., Clark G., Pickering L., Stamp G., Gore M., Szallasi Z., Downward J., Futreal P.A., Swanton C. Intratumor heterogeneity

and branched evolution revealed by multiregion sequencing // N. Engl. J. Med. – 2012. – Vol.366. – P.883892.

27. Giancotti F.G. Mechanisms governing metastatic dormancy and reactivation // Cell. – 2013. – Vol.155. – P.750764.

28. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., Castiglione M., Tu D., Shepherd L.E., Pritchard K.I.,

Livingston R.B., Davidson N.E., Norton L., Perez E.A., Abrams J.S., Therasse P., Palmer M.J., Pater J.L. A randomized trial of

letrozole in postmenopausal women after five years of tamoxifen therapy for earlystage breast cancer // N. Engl. J. Med.

– 2003. – Vol.349. – P.1793802.

29. Goss P.E., Chambers A.F. Does tumour dormancy offer a therapeutic target? // Nat. Rev. Cancer. – 2010. – Vol.10. – P.871877.

30. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., Lander E.S. Identification of selective inhibitors of

cancer stem cells by highthroughput screening // Cell. – 2009. – Vol.138. – P.645659.

31. Hadad S., Iwamoto T., Jordan L., Purdie C., Bray S., Baker L., Jellema G., Deharo S., Hardie D.G., Pusztai L., Moulder

Thompson S., Dewar J.A., Thompson A.M. Evidence for biological effects of metformin in operable breast cancer: a preoperative,

windowofopportunity, randomized trial // Breast Cancer Res Treat. – 2011. – Vol.128. – P.783794.

32. Hamid O., Robert C., Daud A, Hodi F.S., Hwu W.J., Kefford R., Wolchok J.D., Hersey P., Joseph R.W., Weber J.S., Dronca R.,

Gangadhar T.C., Patnaik A., Zarour H., Joshua A.M., Gergich K., ElassaissSchaap J., Algazi A., Mateus C., Boasberg P., Tumeh P.C.,

Chmielowski B., Ebbinghaus S.W., Li X.N., Kang S.P., Ribas A. Safety and tumor responses with lambrolizumab (antiPD1) in

melanoma // N. Engl. J. Med. – 2013. – Vol.369. – P.134144.

33. Hanahan D., Weinberg R.A. The hallmarks of cancer // Cell. – 2000. – Vol.100. – P.5770.

34. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation // Cell. – 2011. – Vol.144. – P.646674.

35. Hemmati H.D., Nakano I., Lazareff J.A., MastermanSmith M., Geschwind D.H., BronnerFraser M., Kornblum H.I. Cancerous

stem cells can arise from pediatric brain tumors // Proc. Natl. Acad. Sci USA. – 2003. – Vol.100. – P.1517815183.

36. HerrerosVillanueva M., Hijona E., Cosme A., Bujanda L. Spontaneous regression of pancreatic cancer: real or a misdiagnosis?

// World J. Gastroenterol. – 2012. – Vol.18. – P.29022908.

37. Hirsch H.A., Iliopoulos D., Tsichlis P.N., Struhl K. Metformin selectively targets cancer stem cells, and acts together with

chemotherapy to block tumor growth and prolong remission // Cancer Res. – 2009. – Vol.69. – P.75077511.

38. Jakobsen J.N., Sшrensen J.B. Intratumor heterogeneity and chemotherapyinduced changes in EGFR status in nonsmall

cell lung cancer // Cancer Chemother Pharmacol. – 2012. – Vol.69. – P.289299.

39. Jessy T. Immunity over inability: The spontaneous regression of cancer // J. Nat. Sci Biol. Med. – 2011. – Vol.2. – P.4349.

40. Kalialis L.V., Drzewiecki K.T., Klyver H. Spontaneous regression of metastases from melanoma: review of the literature /

/ Melanoma Res. – 2009. – Vol.19. – P.275282.

41. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., Redfern C.H., Ferrari A.C., Dreicer R., Sims R.B., X. u

Y., Frohlich M.W., Schellhammer P.F. IMPACT Study Investigators. SipuleucelT immunotherapy for castrationresistant prostate

cancer // N. Engl. J. Med. – 2010. – Vol.363. – P.411422.

42. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., Schreiber R.D. Demonstration of an interferon gamma

dependent tumor surveillance system in immunocompetent mice // Proc. Natl. Acad. Sci USA. – 1998. – Vol.95. – P.75567561.

43. Karrison T.G., Ferguson D.J., Meier P. Dormancy of mammary carcinoma after mastectomy // J. Natl. Cancer Inst. – 1999.

– Vol.91. – P.8085.

44. Klein C.A. Framework models of tumor dormancy from patientderived observations // Curr. Opin. Genet. Dev. – 2011.

– Vol.21. – P.4249.

45. Kleinsmith L.J., Pierce G.B. Jr. Multipoetntiality of single empryonal carcinoma cells // Cancer Res. – 1964. – Vol.24. –

P.15441551.

46. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., Smyth M.J., Schreiber R.D. Adaptive immunity maintains

occult cancer in an equilibrium state // Nature. – 2007. – Vol.450. – P.903907.

47. Kosmidou V., Oikonomou E., Vlassi M., Avlonitis S., Katseli A., Tsipras I., Mourtzoukou D., Kontogeorgos G., Zografos G.,

Pintzas A. Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation

profile differences and their therapeutic implications // Hum. Mutat. – 2014. – Vol.35. – P.329440.

48. Kreso A., O’Brien C.A., van Galen P., Gan O.I., Notta F., Brown A.M., Ng K., Ma J., Wienholds E., Dunant C., Pollett A., Gallinger

S., McPherson J., Mullighan C.G., Shibata D., Dick J.E. Variable clonal repopulation dynamics influence chemotherapy response

in colorectal cancer // Science. – 2013. – Vol.339. – P.543548.

49. Kumar T., Patel N., Talwar A. Spontaneous regression of thoracic malignancies // Respir. Med. – 2010. – Vol.104. –

P.15431550.

50. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., CaceresCortes J., Minden M., Paterson B., Caligiuri M.A., Dick

J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice // Nature. – 1994. – Vol.367.

– P.645648.

51. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., Wicha M., Clarke M.F., Simeone D.M. Identification of pancreatic

cancer stem cells // Cancer Res. – 2007. – Vol.67. – P.10301037.

52. Mattsson J.S., ImgenbergKreuz J., Edlund K., Botling J., Micke P. Consistent mutation status within histologically

heterogeneous lung cancer lesions // Histopathology. – 2012. – Vol.61. – P.744748.

53. Meng S., Tripathy D., Frenkel E.P., Shete S., Naftalis E.Z., Huth J.F., Beitsch P.D., Leitch M., Hoover S., Euhus D., Haley B.,

Morrison L., Fleming T.P., Herlyn D., Terstappen L.W., Fehm T., Tucker T.F., Lane N., Wang J., Uhr J.W. Circulating tumor cells in

patients with breast cancer dormancy // Clin. Cancer Res. – 2004. – Vol.10. – P.81528162.

54. Monzani E., Facchetti F., Galmozzi E., Corsini E., Benetti A., Cavazzin C., Gritti A., Piccinini A., Porro D., Santinami M.,

Invernici G., Parati E., Alessandri G., La Porta C.A. Melanoma contains CD133 and ABCG2 positive cells with enhanced

tumourigenic potential // Europ. J. Cancer. – 2007. – Vol.43. – P.935946.

55. Naumov G.N., Townson J.L., MacDonald I.C., Wilson S.M., Bramwell V.H., Groom A.C., Chambers A.F. Ineffectiveness of

doxorubicin treatment on solitary dormant mammary carcinoma cells or latedeveloping metastases // Breast. Cancer. Res.

Treat. – 2003. – Vol.82. – P.199206.

56. Naumov G.N., Bender E., Zurakowski D., Kang S.Y., Sampson D., Flynn E., Watnick R.S., Straume O., Akslen L.A., Folkman J.,

Almog N. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype // J. Natl. Cancer Inst.

– 2006. – Vol.98. – P.316325.

57. Nauts H.C., Fowler G.A., Bogatko F.H. A review of the influence of bacterial infection and of bacterial products (Coley’s

toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley’s mixed toxins, in which

diagnosis was confirmed by microscopic examination selected for special study // Acta Med Scand Suppl. – 1953. – Vol.276.

– P.1103.

58. Nauts H.C. Bacteria and cancer—antagonisms and benefits // Cancer Surv. – 1989. – Vol.8. – P.713723.

59. Nielsen M., Thomsen J.L., Primdahl S., Dyreborg U., Andersen J.A. Breast cancer and atypia among young and middleaged

women: a study of 110 medicolegal autopsies // Brit. J. Cancer. – 1987. – Vol.56. – P.814819.

60. Ning X., Shu J., Du Y., Ben Q., Li Z. Therapeutic strategies targeting cancer stem cells // Cancer Biol. Ther. – 2013. – Vol.14.

– P.295303.

61. Niraula S., Dowling R.J., Ennis M., Chang M.C., Done S.J., Hood N., Escallon J., Leong W.L., McCready D.R., Reedijk M., Stambolic

V., Goodwin P.J. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study // Breast. Cancer.

Res. Treat. – 2012. – Vol.135. – P.821830.

62. O’Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in

immunodeficient mice // Nature. – 2007. – Vol.445. – P.106110.

63. O’Connor M.L., Xiang D., Shigdar S., Macdonald J., Li Y., Wang T., Pu C., Wang Z., Pierce G.B., Speers W.C. Tumors as caricatures

of the process of tissue renewal: prospects for therapy by directing differentiation // Cancer Res. – 1988. – Vol.48. – P.1996

2004.

64. Oquiсena S., GuillenGrima F., Iсarrairaegui M., Zozaya J.M., Sangro B. Spontaneous regression of hepatocellular carcinoma:

a systematic review // Europ. J. Gastroenterol Hepatol. – 2009. – Vol.21. – P.254257.

65. Papac R.J. Spontaneous regression of cancer // Cancer Treat. Rev. – 1996. – Vol.22. – P.395423.

66. Patel L.R., Nykter M., Chen K., Zhang W. Cancer genome sequencing: understanding malignancy as a disease of the

genome, its conformation, and its evolution // Cancer Lett. – 2013. – Vol.340. – P.152160.

67. Podlaha O., Riester M., De S., Michor F. Evolution of the cancer genome // Trends Genet. – 2012. – Vol.28. – P.155163.

68. Qiao L., Duan W. Cancer stem cells: A contentious hypothesis now moving forward // Cancer Lett. – 2014. – Vol.344. –

P.180187.

69. Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., Morrison S.J. Efficient tumour formation by single human

melanoma cells // Nature. – 2008. – Vol.456. – P.593598.

70. Randolph A.C., Tharalson E.M., Gilani N. Spontaneous regression of hepatocellular carcinoma is possible and might have

implications for future therapies // Europ. J. Gastroenterol. Hepatol. – 2008. – Vol.20. – P.804809.

71. Riethdorf S., Wikman H., Pantel K. Review: Biological relevance of disseminated tumor cells in cancer patients // Int. J.

Cancer. – 2008. – Vol.123. – P.19912006.

72. Richetta A.G., Mancini M., Torroni A., Lorè B., Iannetti G., Sardella B., Calvieri S. Total spontaneous regression of advanced

merkel cell carcinoma after biopsy: review and a new case // Dermatol Surg. – 2008. – Vol.34. – P.815822.

73. Richman S.D., Chambers P., Seymour M.T., Daly C., Grant S., Hemmings G., Quirke P. Intratumoral heterogeneity of KRAS

and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and costeffectiveness of multiple sample

testing // Anal. Cell Pathol (Amst). – 2011. – Vol.34. – P.6166.

74. Sakr W.A., Grignon D.J., Haas G.P., Schomer K.L., Heilbrun L.K., Cassin B.J., Powell J., Montie J.A., Pontes J.E., Crissman J.D.

Epidemiology of high grade prostatic intraepithelial neoplasia // Pathol Res Pract. – 1995. – Vol.191. – P.838841.

75. Saphner T., Tormey D.C., Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy // J. Clin.

Oncol. – 1996. – Vol.14. – P.27382746.

76. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion

// Science. – 2011. – Vol.331. – P.15651570.

77. Sengupta N., MacFie T.S., MacDonald T.T., Pennington D., Silver A.R. Cancer immunoediting and “spontaneous” tumor

regression // Pathol Res Pract. – 2010. – Vol.206. – P.18.

78. Senovilla L., Vitale I., Martins I., Tailler M., Pailleret C., Michaud M., Galluzzi L., Adjemian S., Kepp O., NisoSantano M., Shen

S., Mariсo G., Criollo A., Boilиve A., Job B., Ladoire S., Ghiringhelli F., Sistigu A., Yamazaki T., RelloVarona S., Locher C., Poirier

Colame V., Talbot M., Valent A., Berardinelli F., Antoccia A., Ciccosanti F., Fimia G.M., Piacentini M., Fueyo A., Messina N.L., Li M.,

Chan C.J., Sigl V., Pourcher G., Ruckenstuhl C., CarmonaGutierrez D., Lazar V., Penninger J.M., Madeo F., LуpezOtín C., Smyth M.J.,

Zitvogel L., Castedo M., Kroemer G. An immunosurveillance mechanism controls cancer cell ploidy // Science. – 2012. –

Vol.337. – P.16781684.

79. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., Schreiber R.D. IFNgamma and lymphocytes prevent

primary tumour development and shape tumour immunogenicity // Nature. – 2001. – Vol.410. – P.11071111.

80. Strauss D.C., Thomas J.M. Transmission of donor melanoma by organ transplantation // Lancet Oncol. – 2010. – Vol.11.

– P.790796.

81. Stutman O. Tumor development after 3methylcholanthrene in immunologically deficient athymicnude mice // Science.

– 1974. – Vol.183. – P.534536.

82. Sugihara E., Saya H. Complexity of cancer stem cells // Int. J. Cancer. – 2013. – Vol.132. – P.12491259.

83. Penn I. Posttransplant malignancy: the role of immunosuppression // Drug Saf. – 2000. – Vol.23. – P.101113.

84. Thomas J.A., Badini M. The role of innate immunity in spontaneous regression of cancer // Indian J. Cancer. – 2011. –

Vol.48. – P.246251.

85. Tsao H., Cosimi A.B., Sober A.J. Ultralate recurrence (15 years or longer) of cutaneous melanoma // Cancer. – 1997. –

Vol.79. – P.23612370.

86. Vajdic C.M., McDonald S.P., McCredie M.R., van Leeuwen M.T., Stewart J.H., Law M., Chapman J.R., Webster A.C., Kaldor J.M.,

Grulich A.E. Cancer incidence before and after kidney transplantation // JAMA. – 2006. – Vol.296. – P.28232831.

87. Uhr J.W., Pantel K. Controversies in clinical cancer dormancy // Proc. Natl. Acad. Sci USA. – 2011. – Vol.108. – P.12396

12400.

88. Valenzano Menada M., Moioli M., Garaventa A., Nozza P., Foppiano M., Trimarchi N., Fulcheri E. Spontaneous regression

of transplacental metastases from maternal melanoma in a newborn: case report and review of the literature // Melanoma

Res. – 2010. – Vol.20. – P.443449.

89. Vermeulen L., de Sousa e Melo F., Richel D.J., Medema J.P. The developing cancer stemcell model: clinical challenges and

opportunities // Lancet Oncol. – 2012, Feb. – Vol.13(2). – e8389.

90. Vignot S., Frampton G.M., Soria J.C., Yelensky R., Commo F., Brambilla C., Palmer G., MoroSibilot D., Ross J.S., Cronin M.T.,

André F., Stephens P.J., Lazar V., Miller V.A., Brambilla E. Nextgeneration sequencing reveals high concordance of recurrent

somatic alterations between primary tumor and metastases from patients with nonsmallcell lung cancer // J. Clin. Oncol. –

2013. – Vol.31. – P.21672172.

91. Weckermann D., Polzer B., Ragg T., Blana A., Schlimok G., Arnholdt H., Bertz S., Harzmann R., Klein C.A. Perioperative

activation of disseminated tumor cells in bone marrow of patients with prostate cancer // J. Clin. Oncol. – 2009. – Vol.27. –

P.15491556.

92. WeedonFekjaer H., Lindqvist B.H., Vatten L.J., Aalen O.O., Tretli S. Breast cancer tumor growth estimated through

mammography screening data // Breast. Cancer. Res. – 2008. – Vol.10. – R41.

93. Wolchok J.D., Hoos A., O’Day S., Weber J.S., Hamid O., Lebbé C., Maio M., Binder M., Bohnsack O., Nichol G., Humphrey R.,

Hodi F.S. Guidelines for the evaluation of immune therapy activity in solid tumors: immunerelated response criteria // Clin.

Cancer Res. – 2009. – Vol.15. – P.74127420.

94. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., Segal N.H., Ariyan C.E., Gordon R.A., Reed K.,

Burke M.M., Caldwell A., Kronenberg S.A., Agunwamba B.U., Zhang X., Lowy I., Inzunza H.D., Feely W., Horak C.E., Hong Q., Korman

A.J., Wigginton J.M., Gupta A., Sznol M. Nivolumab plus ipilimumab in advanced melanoma // N. Engl. J. Med. – 2013. – Vol.369.

– P.122133.

95. Yates L.R., Campbell P.J. Evolution of the cancer genome // Nat. Rev. Genet. – 2012. – Vol.13. – P.795806.